Malcova Inc.
Newark, CA
- UEI
- GSB6L7B1FB13
- CAGE
- 9BXA8
- Primary NAICS
- 334517 Irradiation Apparatus Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 39655 Eureka Dr, Newark, CA 94560, USA
- Website
- malcova.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,004,344 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $1,998,128 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $1,004,344 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Proposed research qualifies as development (per its definition in far 35.001) as primary focus of the proposed… | Food and Drug Administration | $1,004,344 | |
| Sbir topic 401 phase II | National Cancer Institute (NIH) | $1,998,128 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: non-planar spectral breast computed tomography (CT) | National Science Foundation | $1,000,000 | |
| A comprehensive imaging solution for dense breast cancer screening and diagnostics | National Cancer Institute (NIH) | $2,842,165 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| QT Imaging, Inc. | Novato, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Empiri, Inc. | Houston, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Lumo Imaging LLC | Potomac, MD | 339112 Surgical and Medical Instrument Manufacturing |
| Invenio Imaging Inc. | San Jose, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Cellsight Technologies, Inc. | San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Malcova Inc., a woman-owned and minority-owned small business manufacturer based in Newark, California, develops advanced breast cancer imaging devices and related diagnostic technologies as a prime recipient under federal contracts and grants, with no subcontractor activity across its recent federal footprint. The company operates exclusively as a prime across four awards spanning the National Cancer Institute (NCI), the National Science Foundation (NSF), and the Food and Drug Administration (FDA), competing without set-asides on research and development work valued at approximately three million dollars in combined potential.
Malcova's capability portfolio centers on breast imaging modality development, particularly computed tomography and spectral imaging technologies designed for dense-breast cancer screening and detection. Recent work includes a $2.0 million Small Business Innovation Research (SBIR) Phase II contract from NCI awarded September 2023 (ultimate completion September 2025) for development of patient-derived anthropomorphic phantoms to enable automated, objective assessment of breast imaging systems. Malcova also received a $1.0 million NSF Technology, Innovation, and Partnerships grant (CFDA 47.084) from May 2023 through April 2024 to develop a novel non-planar spectral breast computed tomography device designed for high-resolution 3D imaging without breast compression, targeting women with dense breast tissue. The company's most recent work is a $1.004 million firm fixed price FDA contract awarded June 2026 for development of a digital twin model to evaluate breast cancer imaging modalities, with completion targeted for June 2027.
Customer concentration is narrowly distributed across three agencies: the National Cancer Institute holds two awards (combined potential value two million dollars), while the FDA and NSF each account for one award. NCI's two awards dominate the portfolio both by count and dollar share. The company has delivered $1.0 million in SCI-reportable invoiced revenue in FY2024 across 3.3 FTEs on federal service contracts, with government-paid rates consistently at $146.05 per hour — a flat rate posture across the decile range. Two awards (combined potential value one million dollars) face ultimate completion within the next twenty-four months, creating near-term recompete exposure. Malcova operates without subcontractor engagement on its SCI-reportable contracts, building its delivery entirely with internal staff.
Quick answers
Is Malcova Inc. registered in SAM.gov?
Yes. Malcova Inc.'s SAM.gov registration is active through February 16, 2027.
How much has Malcova Inc. received in federal contracts?
Federal contracts obligated $3,002,472 to Malcova Inc. in fiscal years 2023 through 2027.
What is Malcova Inc.'s most recent federal award?
Malcova Inc.'s most recent federal contract award is Proposed research qualifies as development (per its definition in far 35.001) as primary focus of the proposed… (75F40126C00019), from Food and Drug Administration, on June 8, 2026.
On GovTribe
See Malcova Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors